R. Schmidt^, C.C. Ward^, R. Dajani, Z. Armour-Garb, M. Ota, V. Allain, R. Hernandez, M. Layeghi, G. Xing, L. Goudy, D. Dorovskyi, C. Wang, Y.Y. Chen, C.J. Ye, B.R. Shy, L.A. Gilbert, J. Eyquem, J.K. Pritchard, S.E. Dodgson, A. Marson^ Base-editing mutagenesis maps alleles to tune human T cell functions. Nature (2023) *Equal contributions, ^Co-corresponding
K. Mandal, G. Wicaksono, C. Yu, J.J. Adams, M.R. Hoopmann, W.C. Temple, A. Izgutdina, B.P. Escobar, M. Gorelik, C.H. Ihling, M.A. Nix, A. Naik, W.H. Xie, J. Hübner, L.A. Rollins, S.M. Reid, E. Ramos, C. Kasap, V. Steri, J.A.C. Serrano, F. Salangsang, P. Phojanakong, M. McMillan, V. Gavallos, A.D. Leavitt, A.C. Logan, C.M. Rooney, J. Eyquem, A. Sinz, B.J. Huang, E. Stieglitz, C.C. Smith, R.L. Moritz, S.S. Sidhu, L. Huang, A.P. Wiita. Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target. Nature Cancer 4, 1592–1609 (2023).
C.A. Tsuchida*, N. Brandes*, R. Bueno*, M. Trinidad, T. Mazumder, B. Yu, B. Hwang, C. Chang, J. Liu, Y. Sun, C.R. Hopkins, K.R. Parker, Y. Qi, A.T. Satpathy, E.A. Stadtmauer, J.H.D. Cate, J. Eyquem, J.A. Fraietta, C.H. June, H.Y. Chang, C.J. Ye^, J.A. Doudna^. Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells. Cell 186, 4567–4582.e20 (2023). *Equal contributions, ^Co-corresponding authors
F. Blaeschke, Y.Y. Chen, R. Apathy, B. Daniel, A.Y. Chen, P.A. Chen, K. Sandor, W. Zhang, Z. Li, C.T. Mowery, T.N. Yamamoto, W.A. Nyberg, A. To, R. Yu, R. Bueno, M.C. Kim, R. Schmidt, D.B. Goodman, T. Feuchtinger, J. Eyquem, C.J. Ye, J. Carnevale, A.T. Sathpathy, E. Shifrut, T.L. Roth^, A. Marson^. Modular pooled discovery of synthetic knockin sequences to program durable cell therapies. Cell 186, P4216–4234.E33 (2023). ^Co-corresponding authors
Y. Wu^, Z. Huang, Y. Liu*, C.W. Yoon, K. Sun, Y. Situ, P. Ho, Z. Yuan, L. Zhu, J. Eyquem, Y. Zhao, T. Liu, G.A. Kwong, S. Chien, Y. Wang^. Spatiotemporal control of genomics and epigenomics by ultrasound. bioRxiv (2023). *Equal contributions, ^Co-corresponding authors
D.V. Foss*, J.J. Muldoon*, D.N. Nguyen*, D. Carr, S.U. Sahu, J.M. Hunsinger, S.K. Wyman, N. Krishnappa, R. Mendonsa, E.V. Schanzer, B.R. Shy, V.S. Vykunta, V. Allain, Z. Li, A. Marson^, J. Eyquem^, R.C. Wilson^. Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes. Nature Biomedical Engineering 7, 647–660 (2023). *Equal contributions, ^Co-corresponding authors
A. Odak, H. Yuan, J. Feucht, V.A. Cantu, J. Mansilla-Soto, F. Kogel, J. Eyquem, J.K. Everett, F.D. Bushman, C. Leslie, M. Sadelain. Novel extragenic genomic safe harbors for precise therapeutic T cell engineering. Blood 141, 2698–2712 (2023).
W.A. Nyberg*, J. Ark*, A. To, S. Clouden, G. Reeder, J.J. Muldoon, J.-Y. Chung, W.H. Xie, V. Allain, Z. Steinhart, C. Chang, A. Talbot, S. Kim, A. Rosales, L.P. Havlik, H. Pimentel, A. Asokan^, J. Eyquem^. An evolved AAV variant enables efficient genetic engineering of murine T cells. Cell 186, 446–460.e19 (2023). *Equal contributions, ^Co-corresponding authors
%20(1).jpg)
.png)
.jpg)
.jpg)
%20(1).jpg)
.jpg)
.webp)
.jpg)
%20(1).jpg)
.webp)
.png)
.svg)